Texting to Promote Mobility in Overweight/Obese Adults with Peripheral Arterial Disease. This study is being conducted at the University of Kansas School of Medicine in Wichita, KS.

The purpose of this study is to compare the clinical benefits of CoQ10 and D-ribose taken by
patients who have diastolic heart failure, or heart failure with preserved ejection fraction
(HFpEF).

This is a multicenter, randomized (1:1; oral treprostinil to placebo), double-blind,
placebo-controlled study in subjects with World Health Organization (WHO) Group 2 pulmonary
hypertension (PH) associated with heart failure with preserved ejection fraction (HFpEF).
Once randomized, subjects will take the initial dose of study drug at the study site on the
day of randomization. Subjects will return to the study site for visits scheduled at Weeks 6,
12, 18, and 24. The treatment phase of the study will last approximately 24 weeks.

The purpose of this study is to evaluate whether a blood pressure treatment strategy during pregnancy to achieve targets that are recommended for non-pregnant reproductive-age adults (

Carotid revascularization for primary prevention of stroke (CREST-2) is two independent
multicenter, randomized controlled trials of carotid revascularization and intensive medical
management versus medical management alone in patients with asymptomatic high-grade carotid
stenosis. One trial will randomize patients in a 1:1 ratio to endarterectomy versus no
endarterectomy and another will randomize patients in a 1:1 ratio to carotid stenting with
embolic protection versus no stenting. Medical management will be uniform for all randomized
treatment groups and will be centrally directed.

This study is a prospective, non-randomized, multi-center study of subjects implanted with
an SJM pacemakers, implantable cardioverter defibrillator (ICD), and cardiac
resynchronization therapy (CRT) devices who are clinically indicated for a non-thoracic MRI
scan.

This study compares EG-1962 to enteral nimodipine in the treatment of aneurysmal
subarachnoid hemorrhage.

This study is a prospective, multi-center, randomized, double-blind placebo-controlled study
of subjects receiving the HM II LVAD as per the current FDA approved indications for use.

ADAPTABLE is a pragmatic clinical trial in which 20,000 patients who are at high risk for ischemic events will be randomly assigned in a 1:1 ratio to receive an aspirin dose of 81 mg/day vs. 325 mg/day. Study participants will be enrolled over 24 months. Maximum follow-up will be 30 months. The purpose of the study is to identify the optimal dose of aspirin for secondary prevention in patients with Atherosclerotic cardiovascular disease (ASCVD).

The Amulet™ device will be evaluated for safety and efficacy by demonstrating its
performance is non-inferior to the commercially available WATCHMAN® left atrial appendage
closure device in patients with non-valvular atrial fibrillation. Patients who are eligible
for the trial will be randomized to receive either the Amulet device or the WATCHMAN device
and will be followed for 5 years after device implant.

Pages